Autopsy report · NCT02399072
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Cause of deathRegulatory or ethics
“There is no longer a plan to pursue an approval of lampalizumab.”
Life of this trial
- Ran for about 2 years 10 months before it stopped.
- 202 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Conditions
- Geographic Atrophy
- Interventions
- No intervention
- Participants
- 202
- Sites
- 63
- Countries
- Argentina, Australia, Brazil, Canada, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.